|
LITTLE FALLS, NJ (April 29, 2008) - Sentrx, the leading provider of drug safety services, announced today that the company signed five new multi-year contracts in the first quarter of 2008. Sentrx now has more than thirty active clients.
Since its inception, Sentrx has built a strong reputation for providing reliable managed safety systems and adverse event reporting services. The multi-year contracts initiated in the first quarter of 2008 include:
Additionally, shorter-term safety system consulting projects were signed with a large biotechnology company and an international generic manufacturer. First quarter engagements successfully completed include a pharmacovigilance assessment at a growing specialty pharmaceutical company and validation script-writing for a new safety system implementation at a large pharmaceutical company.
"This has been one of the most successful quarters in Sentrx history," said Joseph Albano, Chief Executive Officer of Sentrx. "We appreciate the confidence our newest clients have placed in us, and we will strive to exceed their expectations."
To accommodate growth in staff and technology, Sentrx recently moved to new office space in the Overlook at Great Notch building in Little Falls, NJ, expanding and joining three floors of operations into one.
About Sentrx
Sentrx is a leading provider of technology-enabled solutions and services for global drug safety. Its mission is to help pharmaceutical, biotechnology, medical device, and consumer health companies document the safety profile of their products during clinical development and post-approval, enabling them to minimize risks and maximize benefits. Through its multilingual Safety Response Center, Sentrx delivers a unique combination of highly skilled people, exclusive technology, and best practices in drug safety monitoring. To learn more about Sentrx, please call 1-888-399-8032, extension 261, or follow the links below.
|
